ACRS
Price
$1.56
Change
-$0.05 (-3.11%)
Updated
Jun 5 closing price
Capitalization
167.84M
61 days until earnings call
IBRX
Price
$2.90
Change
-$0.03 (-1.02%)
Updated
Jun 5 closing price
Capitalization
2.56B
61 days until earnings call
Interact to see
Advertisement

ACRS vs IBRX

Header iconACRS vs IBRX Comparison
Open Charts ACRS vs IBRXBanner chart's image
Aclaris Therapeutics
Price$1.56
Change-$0.05 (-3.11%)
Volume$637.25K
Capitalization167.84M
ImmunityBio
Price$2.90
Change-$0.03 (-1.02%)
Volume$7.13M
Capitalization2.56B
ACRS vs IBRX Comparison Chart
Loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACRS vs. IBRX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a StrongBuy and IBRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ACRS: $1.55 vs. IBRX: $2.90)
Brand notoriety: ACRS and IBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACRS: 81% vs. IBRX: 79%
Market capitalization -- ACRS: $167.84M vs. IBRX: $2.56B
ACRS [@Biotechnology] is valued at $167.84M. IBRX’s [@Biotechnology] market capitalization is $2.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green whileIBRX’s FA Score has 1 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • IBRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACRS and IBRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while IBRX’s TA Score has 8 bullish TA indicator(s).

  • ACRS’s TA Score: 4 bullish, 4 bearish.
  • IBRX’s TA Score: 8 bullish, 2 bearish.
According to our system of comparison, IBRX is a better buy in the short-term than ACRS.

Price Growth

ACRS (@Biotechnology) experienced а +6.16% price change this week, while IBRX (@Biotechnology) price change was +11.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ACRS is expected to report earnings on Aug 06, 2025.

IBRX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.56B) has a higher market cap than ACRS($168M). IBRX YTD gains are higher at: 13.477 vs. ACRS (-37.500). ACRS has higher annual earnings (EBITDA): -51.72M vs. IBRX (-264.43M). IBRX has more cash in the bank: 150M vs. ACRS (114M). ACRS has higher revenues than IBRX: ACRS (18.7M) vs IBRX (14.7M).
ACRSIBRXACRS / IBRX
Capitalization168M2.56B7%
EBITDA-51.72M-264.43M20%
Gain YTD-37.50013.477-278%
P/E RatioN/AN/A-
Revenue18.7M14.7M127%
Total Cash114M150M76%
Total DebtN/A504M-
FUNDAMENTALS RATINGS
ACRS vs IBRX: Fundamental Ratings
ACRS
IBRX
OUTLOOK RATING
1..100
2113
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
6352
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (4) in the Biotechnology industry is in the same range as ACRS (23) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to ACRS’s over the last 12 months.

ACRS's Profit vs Risk Rating (98) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that ACRS’s stock grew similarly to IBRX’s over the last 12 months.

ACRS's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that ACRS’s stock grew similarly to IBRX’s over the last 12 months.

IBRX's Price Growth Rating (52) in the Biotechnology industry is in the same range as ACRS (63) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to ACRS’s over the last 12 months.

IBRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to ACRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSIBRX
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
85%
Bearish Trend about 1 month ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTDYX35.96N/A
N/A
Invesco EQV Emerging Markets All Cap Y
DNLYX58.11N/A
N/A
BNY Mellon Active MidCap Y
HQIVX20.96N/A
N/A
Hartford Equity Income R6
LOAGX15.73N/A
N/A
Lord Abbett International Growth F3
RPFRX40.65-0.12
-0.29%
Davis Real Estate A

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with PLLWF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then PLLWF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
-3.73%
PLLWF - ACRS
64%
Loosely correlated
N/A
STRRP - ACRS
52%
Loosely correlated
-0.03%
MYNZ - ACRS
40%
Loosely correlated
-2.94%
UFPT - ACRS
39%
Loosely correlated
+1.62%
IBRX - ACRS
34%
Loosely correlated
-0.85%
More

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-0.85%
AXON - IBRX
48%
Loosely correlated
+1.08%
CLRB - IBRX
41%
Loosely correlated
+43.80%
ARRY - IBRX
41%
Loosely correlated
+6.16%
RXRX - IBRX
39%
Loosely correlated
-7.13%
QTTB - IBRX
38%
Loosely correlated
-4.66%
More